

Zarxio can cost $250-$450 per syringe without insurance. Learn how to save with patient assistance programs, copay help, and discount strategies.
If you've been prescribed Zarxio (filgrastim-sndz) to boost your white blood cell count during cancer treatment, you may have experienced sticker shock. A single prefilled syringe of Zarxio can cost $250 to $450 without insurance, and a full treatment course — which may require daily injections for a week or more — can add up to $2,500 to $6,000+ per chemotherapy cycle.
That's a significant amount of money, especially when you're already dealing with the financial stress of cancer treatment. The good news is there are several ways to reduce what you pay for Zarxio, whether you have insurance or not.
In this guide, we'll walk through the real cost of Zarxio in 2026, available discounts and savings programs, and practical strategies to make this medication more affordable.
Let's start with the numbers. Here's what you can expect to pay for Zarxio out of pocket in 2026:
Prices vary by pharmacy and location. Specialty pharmacies may offer different pricing than retail chains. It's always worth comparing prices at multiple pharmacies — and tools like Medfinder can help you find pharmacies with Zarxio in stock so you can compare.
For context, Zarxio is already 40% to 50% cheaper than brand-name Neupogen (filgrastim), which typically costs $500 to $900 per syringe. Being a biosimilar is one of Zarxio's biggest advantages from a cost standpoint.
Most commercial insurance plans and Medicare cover Zarxio, especially for FDA-approved indications like chemotherapy-induced neutropenia. Here's what to know:
Even with insurance, copays for specialty medications like Zarxio can range from $50 to $200+ per fill. If you're in the Medicare Part D "donut hole" or have a high-deductible plan, your out-of-pocket costs could be higher.
Several prescription discount services offer savings on Zarxio. While discounts on biologic medications are often more limited than for common generics, it's still worth checking:
Keep in mind that discount cards typically work best for patients paying cash (no insurance). If you have insurance, your plan's negotiated rate may already be lower than the discount card price. Always compare both options.
Zarxio is a biologic medication, not a traditional small-molecule drug. Discount cards and coupons are less commonly available for biologics, and the discounts tend to be smaller when they are. Don't rely solely on discount cards — the programs below may offer more substantial savings.
If you're uninsured, underinsured, or struggling financially, patient assistance programs (PAPs) can provide Zarxio at significantly reduced cost or even free of charge.
Sandoz is a division of Novartis, and the Novartis Patient Assistance Foundation offers free medication to eligible patients. To qualify, you generally need to:
Contact: 1-800-245-5356 or visit the Novartis PAF website to apply.
Sandoz operates a patient support program called Sandoz One Source that can help with:
NeedyMeds maintains a comprehensive database of patient assistance programs, including those for filgrastim products. Search for "Zarxio" or "filgrastim" to find current programs and eligibility requirements.
RxAssist is another resource for finding patient assistance programs. It's operated by Volunteers in Health Care and provides a searchable database of pharmaceutical company programs.
The Patient Access Network (PAN) Foundation and similar organizations occasionally offer copay assistance grants for oncology medications. These programs open and close based on available funding, so check regularly:
If you receive care at a 340B-covered entity — such as a federally qualified health center, certain hospitals, or community health centers — you may benefit from discounted drug pricing. Ask your treatment center if they participate in the 340B program and whether it affects your Zarxio cost.
Zarxio pricing can vary significantly between pharmacies — sometimes by $100 or more per syringe. Before filling your prescription, compare prices at:
Use Medfinder to find pharmacies with Zarxio in stock, then call to compare prices.
If cost is a major barrier, talk to your doctor about whether a different G-CSF product might be more affordable for your specific situation. Long-acting options like Neulasta or its biosimilar Udenyca cost more per injection but require fewer total injections — which could result in lower overall treatment costs depending on your insurance plan.
Read our full comparison in alternatives to Zarxio.
Many cancer centers have financial counselors or social workers specifically trained to help patients navigate medication costs. They can help you:
Don't hesitate to ask — this is a core part of cancer care, and you're not alone in needing help.
Zarxio is a critical medication, and cost should never be the reason you skip or delay your treatment. Between patient assistance programs, copay support, discount services, and pharmacy price comparisons, there are real ways to make Zarxio more affordable.
Start with the Novartis Patient Assistance Foundation if you're uninsured, or Sandoz One Source if you need copay help with insurance. Use tools like Medfinder and GoodRx to compare prices and find Zarxio in stock near you.
And remember — your oncology team is there to help. Social workers, financial counselors, and patient navigators at your cancer center deal with these issues every day. Ask for help, and you'll likely find more support than you expected.
For information on finding Zarxio during the shortage, read our guide on how to find Zarxio in stock near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.